肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

FDA扩大了礼来的抗VEGFR2单抗Cyramza的适应症，用作肝癌患者的二线治疗

2019-05-11 不详 MedSci原创

VEGFR2单抗Cyramza肝癌
关注

美国食品和药物管理局周五授权礼来的抗血管内皮生长因子受体2(VEGFR2)单抗Cyramza（ramucirumab），作为单一药物用于治疗甲胎蛋白水平至少为400 ng / mL的肝细胞癌（HCC）患者，这些患者之前接受过拜耳的多吉美（索拉非尼）治疗。

美国食品和药物管理局周五授权礼来的抗血管内皮生长因子受体2(VEGFR2)单抗Cyramza（ramucirumab），作为单一药物用于治疗甲胎蛋白水平至少为400 ng / mL的肝细胞癌（HCC）患者，这些患者之前接受过拜耳的多吉美（索拉非尼）治疗。

该批准基于III期REACH-2试验的数据支持。在该研究中，Cyramza和最佳支持治疗的组合中位总生存期为8.5个月，而单独的最佳支持治疗则为7.3个月。

Cyramza最初在美国被批准用于治疗先前治疗过的不可切除或转移性胃癌或胃食管连接腺癌血管生成的患者。该适应症后来扩展到包括治疗胃癌、转移性非小细胞肺癌和转移性结直肠癌。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-11-06 zhu_jun9837

    #肝癌患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-26 12498ca5m83暂无昵称

    #Cyramza#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 644982816_68283321

    #适应症#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 fanweitanzhen

    #VEGF#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 jml2010

    #VEGFR#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 liuyiping

    #GFR#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 ms5768352621950538

    #二线治疗#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-13 d830379

    #抗VEGF#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-12 lovetcm

    仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1969022, encodeId=4fd2196902234, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Wed Nov 06 15:33:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077646, encodeId=915020e7646b2, content=<a href='/topic/show?id=e92b5580bf' target=_blank style='color:#2F92EE;'>#Cyramza#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5580, encryptionId=e92b5580bf, topicName=Cyramza)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sun May 26 06:33:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336779, encodeId=e40b1336e7975, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368524, encodeId=1de5136852427, content=<a href='/topic/show?id=25aa1833e88' target=_blank style='color:#2F92EE;'>#VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18337, encryptionId=25aa1833e88, topicName=VEGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407295, encodeId=207d140e29545, content=<a href='/topic/show?id=d5b01834e3a' target=_blank style='color:#2F92EE;'>#VEGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18347, encryptionId=d5b01834e3a, topicName=VEGFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d8d2627959, createdName=jml2010, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534420, encodeId=2750153442052, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543933, encodeId=f0bc15439333e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621238, encodeId=52081621238a5, content=<a href='/topic/show?id=395f5514e6d' target=_blank style='color:#2F92EE;'>#抗VEGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55147, encryptionId=395f5514e6d, topicName=抗VEGF)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e44a20222078, createdName=d830379, createdTime=Mon May 13 12:33:00 CST 2019, time=2019-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366087, encodeId=e7b336608e09, content=仅仅延长一个月显得有点短，为了在市场上想被广泛推广，可能有相当的难度。, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:25 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366086, encodeId=3b5a36608624, content=只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun May 12 08:44:05 CST 2019, time=2019-05-12, status=1, ipAttribution=)]
    2019-05-12 lovetcm

    只要看看和目前已经上市乐伐替尼，瑞戈非尼相比，是不是也有优势了

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

EASL：VEGFR2单抗Ramucirumab对晚期肝细胞癌的治疗有临床益处

欧洲肝脏研究协会第54届国际肝病会议（EASL）上的最新研究显示，无论肝癌的诱因是什么，ramucirumab对索拉非尼治疗后晚期肝细胞癌和甲胎蛋白升高患者具有临床益处。